COVID-19 relapse associated with SARS-CoV-2 evasion from CD4+ T-cell recognition in an agammaglobulinemia patient
Summary: A 25-year-old patient with a primary immunodeficiency lacking immunoglobulin production experienced a relapse after a 239-day period of persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Viral genetic sequencing demonstrated that SARS-CoV-2 had evolved during...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-05-01
|
| Series: | iScience |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589004223007629 |
| _version_ | 1797835715777658880 |
|---|---|
| author | Ryo Morita Ritsuko Kubota-Koketsu Xiuyuan Lu Tadahiro Sasaki Emi E. Nakayama Yu-chen Liu Daisuke Okuzaki Daisuke Motooka James Badger Wing Yasunori Fujikawa Yuji Ichida Kiyoko Amo Tetsushi Goto Junichi Hara Michinori Shirano Sho Yamasaki Tatsuo Shioda |
| author_facet | Ryo Morita Ritsuko Kubota-Koketsu Xiuyuan Lu Tadahiro Sasaki Emi E. Nakayama Yu-chen Liu Daisuke Okuzaki Daisuke Motooka James Badger Wing Yasunori Fujikawa Yuji Ichida Kiyoko Amo Tetsushi Goto Junichi Hara Michinori Shirano Sho Yamasaki Tatsuo Shioda |
| author_sort | Ryo Morita |
| collection | DOAJ |
| description | Summary: A 25-year-old patient with a primary immunodeficiency lacking immunoglobulin production experienced a relapse after a 239-day period of persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Viral genetic sequencing demonstrated that SARS-CoV-2 had evolved during the infection period, with at least five mutations associated with host cellular immune recognition. Among them, the T32I mutation in ORF3a was found to evade recognition by CD4+ T cells. The virus found after relapse showed an increased proliferative capacity in vitro. SARS-CoV-2 may have evolved to evade recognition by CD4+ T cells and increased in its proliferative capacity during the persistent infection, likely leading to relapse. These mutations may further affect viral clearance in hosts with similar types of human leukocyte antigens. The early elimination of SARS-CoV-2 in immunocompromised patients is therefore important not only to improve the condition of patients but also to prevent the emergence of mutants that threaten public health. |
| first_indexed | 2024-04-09T14:58:03Z |
| format | Article |
| id | doaj.art-f0e08f94d7854578b413062f38f95992 |
| institution | Directory Open Access Journal |
| issn | 2589-0042 |
| language | English |
| last_indexed | 2024-04-09T14:58:03Z |
| publishDate | 2023-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | iScience |
| spelling | doaj.art-f0e08f94d7854578b413062f38f959922023-05-02T04:05:13ZengElsevieriScience2589-00422023-05-01265106685COVID-19 relapse associated with SARS-CoV-2 evasion from CD4+ T-cell recognition in an agammaglobulinemia patientRyo Morita0Ritsuko Kubota-Koketsu1Xiuyuan Lu2Tadahiro Sasaki3Emi E. Nakayama4Yu-chen Liu5Daisuke Okuzaki6Daisuke Motooka7James Badger Wing8Yasunori Fujikawa9Yuji Ichida10Kiyoko Amo11Tetsushi Goto12Junichi Hara13Michinori Shirano14Sho Yamasaki15Tatsuo Shioda16Department of Infectious Diseases, Osaka City General Hospital, Osaka 534-0021, Japan; Department of Viral Infections, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, JapanDepartment of Viral Infections, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, JapanLaboratory of Molecular Immunology, Immunology Frontier Research Center, Osaka University, Osaka 565-0871, JapanDepartment of Viral Infections, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, JapanDepartment of Viral Infections, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, JapanLaboratory of Human Immunology (Single Cell Genomics), Immunology Frontier Research Center, Osaka University, Osaka 565-0871, JapanLaboratory of Human Immunology (Single Cell Genomics), Immunology Frontier Research Center, Osaka University, Osaka 565-0871, JapanDepartment of Infection Metagenomics, Genome Information Research Center, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, JapanLaboratory of Human Immunology (Single Cell Immunology), Immunology Frontier Research Center, Osaka University, Osaka 565-0871, JapanDepartment of Medical Laboratory, Osaka City General Hospital, Osaka 534-0021, JapanDepartment of Pharmacy, Osaka City General Hospital, Osaka 534-0021, JapanDepartment of Pediatric Emergency Medicine, Osaka City General Hospital, Osaka 534-0021, JapanDepartment of Infectious Diseases, Osaka City General Hospital, Osaka 534-0021, JapanDepartment of Pediatric Hematology and Oncology, Osaka City General Hospital, Osaka 534-0021, JapanDepartment of Infectious Diseases, Osaka City General Hospital, Osaka 534-0021, Japan; Corresponding authorLaboratory of Molecular Immunology, Immunology Frontier Research Center, Osaka University, Osaka 565-0871, Japan; Corresponding authorDepartment of Viral Infections, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan; Corresponding authorSummary: A 25-year-old patient with a primary immunodeficiency lacking immunoglobulin production experienced a relapse after a 239-day period of persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Viral genetic sequencing demonstrated that SARS-CoV-2 had evolved during the infection period, with at least five mutations associated with host cellular immune recognition. Among them, the T32I mutation in ORF3a was found to evade recognition by CD4+ T cells. The virus found after relapse showed an increased proliferative capacity in vitro. SARS-CoV-2 may have evolved to evade recognition by CD4+ T cells and increased in its proliferative capacity during the persistent infection, likely leading to relapse. These mutations may further affect viral clearance in hosts with similar types of human leukocyte antigens. The early elimination of SARS-CoV-2 in immunocompromised patients is therefore important not only to improve the condition of patients but also to prevent the emergence of mutants that threaten public health.http://www.sciencedirect.com/science/article/pii/S2589004223007629Immunology |
| spellingShingle | Ryo Morita Ritsuko Kubota-Koketsu Xiuyuan Lu Tadahiro Sasaki Emi E. Nakayama Yu-chen Liu Daisuke Okuzaki Daisuke Motooka James Badger Wing Yasunori Fujikawa Yuji Ichida Kiyoko Amo Tetsushi Goto Junichi Hara Michinori Shirano Sho Yamasaki Tatsuo Shioda COVID-19 relapse associated with SARS-CoV-2 evasion from CD4+ T-cell recognition in an agammaglobulinemia patient iScience Immunology |
| title | COVID-19 relapse associated with SARS-CoV-2 evasion from CD4+ T-cell recognition in an agammaglobulinemia patient |
| title_full | COVID-19 relapse associated with SARS-CoV-2 evasion from CD4+ T-cell recognition in an agammaglobulinemia patient |
| title_fullStr | COVID-19 relapse associated with SARS-CoV-2 evasion from CD4+ T-cell recognition in an agammaglobulinemia patient |
| title_full_unstemmed | COVID-19 relapse associated with SARS-CoV-2 evasion from CD4+ T-cell recognition in an agammaglobulinemia patient |
| title_short | COVID-19 relapse associated with SARS-CoV-2 evasion from CD4+ T-cell recognition in an agammaglobulinemia patient |
| title_sort | covid 19 relapse associated with sars cov 2 evasion from cd4 t cell recognition in an agammaglobulinemia patient |
| topic | Immunology |
| url | http://www.sciencedirect.com/science/article/pii/S2589004223007629 |
| work_keys_str_mv | AT ryomorita covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient AT ritsukokubotakoketsu covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient AT xiuyuanlu covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient AT tadahirosasaki covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient AT emienakayama covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient AT yuchenliu covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient AT daisukeokuzaki covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient AT daisukemotooka covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient AT jamesbadgerwing covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient AT yasunorifujikawa covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient AT yujiichida covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient AT kiyokoamo covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient AT tetsushigoto covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient AT junichihara covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient AT michinorishirano covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient AT shoyamasaki covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient AT tatsuoshioda covid19relapseassociatedwithsarscov2evasionfromcd4tcellrecognitioninanagammaglobulinemiapatient |